Chinese IVD Companies Report Q1 2024 Results

 

On April 19, Autobio released its first quarter 2024 results report, in which the company realized total operating revenue of RMB 1.089 billion in the first quarter, up 5.09% year-on-year, and net profit attributable to the mother of 324 million yuan, up 33.93% year-on-year.

 

On April 19, Dirui released its first quarter 2024 results report, in which the company achieved total operating income of RMB 663 million in the first quarter, a year-on-year increase of 99.60%; net profit attributable to the mother of RMB 122 million, a year-on-year increase of 56.73%.

 

On April 22, Wondfo released its first quarter 2024 results report, in which the company realized total operating income of RMB 861 million in the first quarter, an increase of 3.54% year-on-year, and net profit attributable to the mother of RMB 218 million, an increase of 7.2% year-on-year.

 

On April 26, Mindray announced its first quarterly report for 2024, realizing operating revenue of RMB 9.373 billion, up 12.06% year-on-year; net profit attributable to shareholders of listed companies was RMB 3.160 billion, up 22.90% year-on-year. Medical R&D investment of RMB 1.030 billion, accounting for 10.99% of operating income.

On April 26, Snibe released the first quarter 2024 results report, in the first quarter the company achieved total operating income of RMB 1.021 billion, an increase of 16.62% year-on-year, and achieved net profit of RMB 426 million, an increase of 20.04% year-on-year.　

Autobio and Sekisui Launched a comprehensive strategic partnership for biochemical reagents in China

 

On April 22, 2024, the signing ceremony of biochemical products cooperation agreement between Beijing Autobio and Sekisui Medical was held in Beijing. The two parties indicated that they will launch a full range of strategic cooperation on biochemical reagents in China in the future, making full use of their respective brand accumulation, product reserves and technical advantages in the field of in vitro diagnostics to realize win-win collaboration in the biochemical market.

The first FDA-approved fully automated urine analyzer in China

 

On April 29, 2024, URIT UC-1800 Urine Analyzer successfully passed the U.S. FDA approval.UC-1800, as an important part of the modular urine analysis pipeline of URIT US-2000 series artificial intelligence, has a dry chemical analysis module with a single measuring speed of up to 480T/H, the world's first comprehensive testing speed, which is capable of handling the needs of the high-end market with ease. At the same time, UC-1800 is the world's first urine dry chemistry analyzer that can achieve charts and traceable results, with a maximum of 500 test strips placed in a single run, constant temperature reaction of dry chemistry test strips, one-key switching of 11-14 different test strip types, easy operation, and stable and reliable test results.